Cefalexin pulsatile - MiddleBrook Pharmaceuticals

Drug Profile

Cefalexin pulsatile - MiddleBrook Pharmaceuticals

Alternative Names: Cephalexin PULSYS; Keflex PULSYS

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MiddleBrook Pharmaceutical
  • Class Antibacterials; Cephalosporins; Small molecules
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Bacterial infections

Most Recent Events

  • 03 Aug 2010 Victory Pharma acquires MiddleBrook Pharmaceuticals
  • 28 Jun 2007 Advancis Pharmaceutical is now called MiddleBrook Pharmaceuticals
  • 31 Dec 2006 Suspended - Phase-I for Bacterial infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top